Clinical Trials Logo

Temporal Lobe Epilepsy clinical trials

View clinical trials related to Temporal Lobe Epilepsy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06269822 Completed - Clinical trials for Temporal Lobe Epilepsy

Autonomic Dysfunction in Temporal Lobe Epilepsy and SUDEP

Start date: September 1, 2022
Phase:
Study type: Observational

The study aimed at detection of autonomic dysfunction among cases with temporal lobe epilepsy; using different electrophysiological techniques. Moreover, it aimed at finding any correlation between electrophysiological tests and SUDEP risk.

NCT ID: NCT05159609 Completed - Clinical trials for Temporal Lobe Epilepsy

Closed Loop Auditory Stimulus in Sleep and epilepsY

CLASSY
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

This is a single-centre pilot study of a non-invasive auditory stimulation during sleep in participants with temporal lobe epilepsy.

NCT ID: NCT02946151 Completed - Clinical trials for Temporal Lobe Epilepsy

Subcutaneous EEG in Epilepsy

Start date: November 2016
Phase: N/A
Study type: Interventional

The study is a two-phase study, which aims to explore the uses of a novel electrode type in detecting epileptic seizures. The electrode is designed for subcutaneous implantation with long-term monitoring in mind.

NCT ID: NCT02844465 Completed - Clinical trials for Temporal Lobe Epilepsy

Stereotactic Laser Ablation for Temporal Lobe Epilepsy

SLATE
Start date: December 2016
Phase: N/A
Study type: Interventional

The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

NCT ID: NCT00595699 Completed - Major Depression Clinical Trials

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

Start date: November 2006
Phase: Phase 4
Study type: Interventional

This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.

NCT ID: NCT00344877 Completed - Clinical trials for Temporal Lobe Epilepsy

Electrical Brain Stimulation to Reduce Epileptic Seizures

Start date: June 19, 2006
Phase: N/A
Study type: Observational

OBJECTIVES: About 15% of patients suffering from focal epilepsy are refractory to available pharmacological treatments. Until now, the only hope for such patients has been the development of new pharmaceutical treatments or epilepsy surgery. In case of inoperability, different types of invasive brain stimulation such as vagus nerve stimulation or deep brain stimulation or non-invasive repetitive TMS have been evaluated to determine their anticonvulsive potential. For rTMS, weak and short lasting seizure reduction has been reported in different epilepsy syndromes. A new, non-invasive stimulation technique, transcranial direct current stimulation (tDCS), was useful to modulate cortical excitability in many cortical areas (M1, visual cortex, frontal cortex). Cathodal tDCS, with a current of 1 mA, induced long-term depression in animal models and reportedly decreased the excitability of both human and animal cerebral cortex. In epilepsy patients suffering from a malformation of cortical development, a single session of cathodal tDCS helped reduce seizures briefly. The purpose of this protocol is to study the effects of repeated applications of tDCS on the excitability of the seizure focus in patients with poorly controlled pharmacologically refractory temporal lobe epilepsy. STUDY POPULATION: We plan to study 56 patients between the ages of 18 and 80 suffering from temporal lobe epilepsy. DESIGN: Subjects will be allocated by blocked randomization to one of two groups (parallel design). Group A will receive cathodal tDCS and group B will receive Sham-tDCS on five consecutive days. Each subject will participate in 9 sessions (1 baseline visit, 5 intervention visits, 3 follow-up visits). The effect of the intervention relative to the sham stimulation will be evaluated by comparing seizure frequency and neuropsychological tests during the 8 weeks before and after the intervention. OUTCOME MEASURES: Primary outcome measure will be the mean seizure frequency per 4 weeks in the tDCS group as compared to the Sham-tDCS group. To analyze the effect of the intervention (tDCS), seizures will be evaluated during a 2x4 week baseline period before tDCS and 2x4 weeks after the intervention. Using these data we will calculate the percentage change of seizures per 4 weeks. Secondary outcome measures will be the scores of the neuropsychological testing (HVLT-R, BVMT-R, CTMT, COWAT) and number of epileptiform discharges in the EEG. Furthermore, th...